Breaks Categories: News

ThursdayMar 10, 2022 12:54 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights’ March Conference to Showcase Curated CEOs, Capital Advisors and Investment Luminaries from Around the World

Microdose Psychedelic Insights, the leading guide to the business of psychedelics, will be hosting the upcoming Psychedelic Capital: March 2022 Conference. The event, slated to take place in an entirely virtual format on Thursday March 24, will feature some of the top companies, latest IPOs, newest opportunities and deepest industry insights within the psychedelics sector. As part of a bimonthly conference series that dives deep into psychedelic medicine investment, the event will introduce investors and attendees to a carefully selected group of CEOs, capital advisors and luminaries from around the world. “Over the last 18 months of hosting the Psychedelic…

Continue Reading

ThursdayMar 03, 2022 11:12 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation Schedule for March Investor Conferences

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that it will be attending three investor conferences in March. The upcoming events include the 34th Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference and Maxim Group’s Virtual Growth Conference. Members of Mydecine’s management team will be available for one-on-one or small group meetings, which may be scheduled by emailing contact@mydecineinc.com. Investor meetings will focus on the company’s research and development pipeline, patent strategies, as well as clinical trials involving targeted drug candidates and therapeutic…

Continue Reading

WednesdayMar 02, 2022 11:14 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Oppenheimer Annual Healthcare Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its Chief Executive Officer Doug Drysdale will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. Drysdale’s presentation is slated to begin at 8:40 a.m. ET on Wednesday, March 16, 2022. Interested parties should visit https://ibn.fm/4Yog7 to register for the event and access the webcast. An archived version of the webcast will be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/JiX1x About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working…

Continue Reading

TuesdayMar 01, 2022 12:25 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Dr. Matthew Johnson of Johns Hopkins University, a leading researcher of drug and substance abuse, will serve as the lead investigator for the multisite study. “The data from John Hopkins University’s ongoing…

Continue Reading

FridayFeb 25, 2022 12:07 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a life sciences holding company dedicated to building a portfolio of assets and biotech solutions. The company has announced its entry into a firm agreement in connection with the sale of its former Cobourg, Ontario-based cannabis processing facility and the 64.43-acre property on which the facility is located (the “transaction”). In consideration of the purchase of the facility, the purchaser has agreed to pay a cash sum of CAD$16,500,000, including a deposit of CAD$660,000 (the “deposit”). FSD Pharma received the deposit on Feb. 24, 2022, and the transaction, which is subject…

Continue Reading

FridayFeb 18, 2022 11:23 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused has announced that subsidiary Adelia Therapeutics Inc. has achieved a milestone outlined in the contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders; the milestone was identified as Year 2 Q2 (iii). According to the transaction agreement, 17,239.5 Cybin class B common shares will be issued to Adelia shareholders when relevant milestones have been met; the class B Shares will be exchangeable for common shares in the capital of Cybin at an exchange rate of 10 to 1. Adelia is working on developing medicinal psychedelics with improved…

Continue Reading

WednesdayFeb 16, 2022 1:27 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns with the first-generation compounds. According to the company, its research findings show the potential for a psilocin analog that may be considered a heart-safe microdose drug, which is a substance consumed at a low enough…

Continue Reading

WednesdayFeb 16, 2022 11:36 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Aegis Virtual Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the Aegis Virtual Conference. The event will span three days, from Feb 23-25, 2022, with Drysdale’s presentation scheduled to begin at 2 p.m. ET on Thursday, Feb. 24. Interested parties should visit https://ibn.fm/eqPBg to listen to the event and access the webcast. An archived webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/PrtCB About Cybin Inc. Cybin is a leading ethical…

Continue Reading

TuesdayFeb 15, 2022 1:19 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), The Chopra Foundation Partner to Uncover Potential of Psychedelic Therapies in Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has entered a strategic partnership with The Chopra Foundation, a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving health and well-being. Under the collaboration, The Chopra Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health. Emerging research shows the potential for psychedelic-assisted therapy to improve the quality of life for people suffering with mental illnesses, including those specific indications that Cybin is targeting, such as major depressive…

Continue Reading

ThursdayFeb 10, 2022 1:50 pm

PsychedelicNewsBreaks – Microdose Psychedelic to Host February Molecular Masterclass: The LSD Conference

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, announced that it will be hosting the Molecular Masterclass: LSD Conference next week. Microdose is hosting the event, scheduled for Feb. 17, 2022, in partnership with MindBio Therapeutics. The all-virtual conference is designed to offer a scientific deep dive into the dynamic field of LSD microdosing exploring the potential of LSD at the intersection of drug development and safety, clinical care and applications, law and regulation, business and markets, science and research, and…

Continue Reading